Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Beta glucans are polysaccharides found in the cell walls of cereals, bacteria, and fungi. They are primarily known for their immune-modulating properties. Emerging scientific research has investigated the potential of beta glucans to support colitis, particularly in animal models of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. Several preclinical studies have shown that beta glucans can reduce inflammation, modulate gut microbiota, and improve mucosal healing in chemically-induced colitis in rodents. The proposed mechanisms include enhancement of the gut barrier, reduction of pro-inflammatory cytokines, and stimulation of beneficial immune responses.

However, evidence in humans is limited. Clinical studies specifically evaluating beta glucans in patients with colitis are scarce. Most human research to date has focused on general immune health or metabolic effects of beta glucans, rather than direct treatment of IBD. As such, while animal and in vitro studies provide a scientific rationale and some promising results, robust clinical trials in humans are lacking.

In summary, there is scientific (not traditional) interest in using beta glucans for colitis, supported mainly by preclinical data. The overall quality and quantity of clinical evidence are currently low, justifying a modest evidence rating of 2 out of 5.

More about Beta Glucans
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Beta Glucans

Products containing Beta Glucans